Literature DB >> 21940767

Mast cell inhibition improves pulmonary vascular remodeling in pulmonary hypertension.

Beatrijs Bartelds1, Rosa Laura E van Loon2, Saffloer Mohaupt2, Hans Wijnberg2, Michael G Dickinson2, Bibiche Boersma2, Janny Takens2, Mirjam van Albada2, Rolf M F Berger2.   

Abstract

BACKGROUND: Pulmonary arterial hypertension (PAH) is a progressive angioproliferative disease with high morbidity and mortality. Although the histopathology is well described, its pathogenesis is largely unknown. We previously identified the increased presence of mast cells and their markers in a rat model of flow-associated PAH. The aim of this study was to test the effect of mast cell stabilization on pulmonary vascular remodeling in experimental PAH.
METHODS: Rats with flow-associated PAH created by monocrotaline and an aorto-caval shunt were treated with the mast cell stabilizer cromolyn and compared with untreated rats and control rats. Further, we treated a group of rats with PAH with an inhibitor (TY-51469) of chymase, one of the mast cell proteases. The effects on pulmonary vascular remodeling and hemodynamics were assessed.
RESULTS: Rats with PAH had increased mast cells, chymase activity, and inflammatory markers. Treatment with mast cell stabilizer attenuated pulmonary vascular remodeling but not hemodynamics. A lower pulmonary chymase activity correlated with more favorable pulmonary vascular remodeling as well as hemodynamics and inflammatory markers.
CONCLUSIONS: We showed in rats with PAH that mast cell stabilization attenuated pulmonary vascular remodeling and that a lower chymase activity correlated with more favorable hemodynamics and pulmonary vascular remodeling. The results of this experimental study support the concept of the use of antiinflammatory therapy by mast cell stabilizers, a group of drugs already licensed for clinical use, to attenuate disease progression in PAH.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21940767     DOI: 10.1378/chest.11-0663

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  25 in total

1.  Inhibition of mast cell-secreted histamine decreases biliary proliferation and fibrosis in primary sclerosing cholangitis Mdr2(-/-) mice.

Authors:  Hannah Jones; Laura Hargrove; Lindsey Kennedy; Fanyin Meng; Allyson Graf-Eaton; Jennifer Owens; Gianfranco Alpini; Christopher Johnson; Francesca Bernuzzi; Jennifer Demieville; Sharon DeMorrow; Pietro Invernizzi; Heather Francis
Journal:  Hepatology       Date:  2016-07-30       Impact factor: 17.425

Review 2.  Inflammation in Pulmonary Arterial Hypertension.

Authors:  Timothy Klouda; Ke Yuan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  H2 receptor antagonists and right ventricular morphology: the MESA right ventricle study.

Authors:  Peter J Leary; R Graham Barr; David A Bluemke; Michael R Bristow; Richard A Kronmal; Joao A Lima; David D Ralph; Corey E Ventetuolo; Steven M Kawut
Journal:  Ann Am Thorac Soc       Date:  2014-11

4.  Platelets from pulmonary hypertension patients show increased mitochondrial reserve capacity.

Authors:  Quyen L Nguyen; Catherine Corey; Pamela White; Annie Watson; Mark T Gladwin; Marc A Simon; Sruti Shiva
Journal:  JCI Insight       Date:  2017-03-09

5.  Mast Cell Inhibition Attenuates Cardiac Remodeling and Diastolic Dysfunction in Middle-aged, Ovariectomized Fischer 344 × Brown Norway Rats.

Authors:  Hao Wang; Jaqueline da Silva; Allan Alencar; Gisele Zapata-Sudo; Marina R Lin; Xuming Sun; Sarfaraz Ahmad; Carlos M Ferrario; Leanne Groban
Journal:  J Cardiovasc Pharmacol       Date:  2016-07       Impact factor: 3.105

6.  Mesenchymal stem cells attenuate vascular remodeling in monocrotaline-induced pulmonary hypertension rats.

Authors:  Jiang Xie; Dayi Hu; Lili Niu; Suping Qu; Shenghao Wang; Shuang Liu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-12-28

Review 7.  Bone marrow-derived vascular modulatory cells in pulmonary arterial hypertension.

Authors:  Emily Lanzola; Samar Farha; Serpil C Erzurum; Kewal Asosingh
Journal:  Pulm Circ       Date:  2013-12       Impact factor: 3.017

Review 8.  Mast cells: an expanding pathophysiological role from allergy to other disorders.

Authors:  Preet Anand; Baldev Singh; Amteshwar Singh Jaggi; Nirmal Singh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-05-06       Impact factor: 3.000

Review 9.  The role of inflammation in hypoxic pulmonary hypertension: from cellular mechanisms to clinical phenotypes.

Authors:  Steven C Pugliese; Jens M Poth; Mehdi A Fini; Andrea Olschewski; Karim C El Kasmi; Kurt R Stenmark
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-11-21       Impact factor: 5.464

10.  New dynamic viewing of mast cells in pulmonary arterial hypertension (PAH): contributors or outsiders to cardiovascular remodeling.

Authors:  Jian Xu; Jingjing Wang; Chengjie Shao; Xiaoning Zeng; Lixiang Sun; Hui Kong; Weiping Xie; Hong Wang
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.